ArticleJournal of cellular and molecular medicine2026
Humanized Antibodies Targeting Ectodomains of IL-6R and GP130 Suppress IL-6/STAT3 Signalling and Tumour Growth in Breast Cancer Models.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Interleukin-6 (IL-6) signalling is a key driver of breast cancer progression, activating pro-survival, pro-inflammatory and metastatic programs through its receptors, IL-6R and GP130. Elevated IL-6 levels correlate with poor prognosis in breast cancer patients and persistent IL-6/STAT3 activation promotes tumour proliferation, metastasis, angiogenesis and therapy resistance. Although therapeutics targeting this pathway have shown promise, most have focused on individual signalling nodes and yielded limited efficacy in breast tumours. In this study, we generated murine monoclonal antibodies targeting ectodomains of IL-6R and GP130 receptors involved in IL-6/IL-6R/GP130 complex formation and humanized the lead candidates E17 (anti-IL-6R) and NA7 (anti-GP130). The resulting humanized antibodies, huE17 and huNA7, exhibited target specificity and effectively inhibited IL-6 induced STAT3 activation and tumour promoting phenotypes in vitro. In vivo evaluation using orthotopic breast cancer xenografts and agarose plug angiogenesis assays showed both individual and combined antibody treatments significantly suppressing tumour growth. Structural modelling suggested that huE17 and huNA7 engage receptor surfaces spanning multiple ectodomains of IL-6R and GP130, consistent with disruption of IL-6/IL-6R/GP130 complex receptor assembly. Together, these findings support the preclinical development of huE17 and huNA7 and the potential of dual IL-6R and GP130 targeting in IL-6-driven breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.